Halozyme Therapeutics revenue and financials

HALO · NASDAQ · USD

$109.72+1.30%+$1.41

Close · October 6, 2026

In the fiscal year ended December 2025, Halozyme Therapeutics reported revenue of $1.4B (+37.55% year over year). Net income was $316.89M, a net margin of 22.7%.

Annual revenue · 2025: $1.4B

$146.69M2016
$316.61M2017
$151.86M2018
$195.99M2019
$267.59M2020
$443.31M2021
$660.12M2022
$829.25M2023
$1.02B2024
$1.4B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +37.55%; 2025 vs 2024
Net income growth: −28.64%; 2025 vs 2024
Net margin: 22.7%; 2024: 43.7%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total assets	2,577	2,673	2,525	2,221	2,054	2,197	2,063	2,118	1,969	1,842	1,733	1,893
Current assets	933	1,003	825	1,329	1,123	1,262	1,085	1,127	988	874	746	879
Cash and equivalents	163	310	134	420	61.9	176	116	154	188	165	118	274
Short-term investments	67.9	8.9	9.0	282	486	572	480	512	341	299	218	209
Receivables	456	458	441	346	316	305	308	286	215	196	234	217
Inventory	137	155	176	186	182	165	142	131	159	169	128	129
Net property, plant and equipment	84.3	82.2	82.1	71.4	71.5	72.8	75.0	74.5	75.0	78.1	74.9	74.7
Goodwill	582	582	580	417	417	417	417	417	417	417	417	417
Other intangible assets	922	952	981	349	366	384	402	420	437	455	473	491
Current liabilities	344	363	177	837	134	150	139	109	133	132	112	115
Accounts payable	23.6	14.1	20.9	15.4	18.7	20.1	10.2	12.4	15.4	13.3	11.8	19.3
Long-term debt	1,938	1,936	2,143	800	1,509	1,507	1,506	1,504	1,503	1,501	1,499	1,498
Total debt	2,147	2,145	2,143	1,511	1,509	—	—	—	—	—	—	—
Total liabilities	2,434	2,453	2,477	1,717	1,721	1,714	1,700	1,665	1,680	1,664	1,649	1,643
Total equity (incl. minority)	144	220	48.8	504	333	482	364	453	289	178	83.8	249
Retained earnings	151	205	54.8	502	361	478	360	398	261	167	90.6	222